TCL Archive Excitement building toward 2015 goal, NCI director says in FY07 bypass budget request. NCI seeks $5.8 billion. December 2, 2005
TCL Archive The shadow of Iressa lingered over the FDA Oncologic Drugs Advisory Committee as the panel voted down Genasense (Genta Inc.) and RSR13 (Allos Therapeutics Inc.) at its May 3 meeting. If anyone thought the bar had been lowered for drug approvals, they were mistaken. May 7, 2004
TCL Archive FDA To Once Again Review ESA Label To Reflect Results Of Negative Studies. December 7, 2007
